Cargando…

One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study

Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment. The experience in real-world clinical practice is limited. We aimed to explore the efficacy after 1-year TAF treatment. A total of 148 patients (42 H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yi-Cheng, Hsu, Chao-Wei, Chien, Rong-Nan, Tai, Dar-In
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276287/ https://www.ncbi.nlm.nih.gov/pubmed/35758355 http://dx.doi.org/10.1097/MD.0000000000029269

Ejemplares similares

Effect of tenofovir on renal function in patients with chronic hepatitis B
por: Jung, Woo Jin, et al.
Publicado: (2018)

Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study
por: Zheng, Shuqin, et al.
Publicado: (2019)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
por: Lin, Hung-Yao, et al.
Publicado: (2022)

Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
por: Lee, Dohyeong, et al.
Publicado: (2019)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B
por: Chen, Ruochan, et al.
Publicado: (2022)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
por: Ogawa, Eiichi, et al.
Publicado: (2017)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment
por: Yang, Jiezuan, et al.
Publicado: (2017)

Fatal lactic acidosis in hepatitis B virus-associated decompensated cirrhosis treated with tenofovir: A case report
por: Jung, Tae Yang, et al.
Publicado: (2017)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B: A Prospective Observational Study
por: Jia, Wei, et al.
Publicado: (2014)

Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
por: Byrne, Ruth, et al.
Publicado: (2018)

An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
por: Charlton, Michael R., et al.
Publicado: (2020)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
por: Li, Juan, et al.
Publicado: (2021)

Efficacy and safety of vesatolimod in chronic hepatitis B: A systematic review and meta-analysis
por: Omer, Ibrahim, et al.
Publicado: (2023)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B
por: Li, Chang, et al.
Publicado: (2021)

Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA
por: Gao, Wen-Kang, et al.
Publicado: (2022)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data
por: Lim, Young‐Suk, et al.
Publicado: (2022)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study
por: Wang, Chun-Hsiang, et al.
Publicado: (2020)

Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients
por: Liu, Yen-Chun, et al.
Publicado: (2020)

Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy
por: Lee, I-Cheng, et al.
Publicado: (2022)

An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study
por: Chon, Young Eun, et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients
por: Lee, Brian T, et al.
Publicado: (2020)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cm1j90bqhkb6uahjjh7nfq8ogr